Search

Your search keyword '"Patel, Keyur"' showing total 1,844 results

Search Constraints

Start Over You searched for: Author "Patel, Keyur" Remove constraint Author: "Patel, Keyur" Language english Remove constraint Language: english
1,844 results on '"Patel, Keyur"'

Search Results

4. Factors Associated With Coronary Angiography Performed Within 6 Months of Randomization to the Conservative Strategy in the ISCHEMIA Trial

9. Immune evasion phenotype is common in Richter transformation diffuse large B-cell lymphoma variant

11. Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia

13. Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41

15. A global research priority agenda to advance public health responses to fatty liver disease

18. Tumor biology and immune infiltration define primary liver cancer subsets linked to overall survival after immunotherapy

19. Clinicopathologic Features of Therapy-Related Myeloid Neoplasms in Patients with Myeloma in the Era of Novel Therapies

21. Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphoma

23. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML

25. Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes

26. Undetectable Measurable Residual Disease is Associated with Improved Outcomes in AML Irrespective of Treatment Intensity

27. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial

28. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms

30. Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial

33. High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse

34. Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group

39. Ibrutinib–rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial

40. TP53 Y220C mutations in patients with myeloid malignancies.

41. A short report on ADHD detection using convolutional neural networks.

42. Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemia.

44. Standardizing gene product nomenclature—a call to action

45. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations

46. Epstein–Barr-virus-positive large B-cell lymphoma associated with breast implants: an analysis of eight patients suggesting a possible pathogenetic relationship

50. Factors Impacting Clinically Relevant RNA Fusion Assays Using Next-Generation Sequencing

Catalog

Books, media, physical & digital resources